Confocal laser scanning microscope analysis on post-biofilm assessment of biofilmproducing osteomyelitic staphylococcus aureus treated with new gentamicin-nigella sativa fusion emulsion (GNFE) by Yaacob, Khairul Ikhwan et al.
Malaysian Journal of Microscopy 11: 68-73 (2015)                                                       ISSN: 1823-7010 
 
CONFOCAL LASER SCANNING MICROSCOPE ANALYSIS 
ON POST-BIOFILM ASSESSMENT OF BIOFILM-
PRODUCING OSTEOMYELITIC STAPHYLOCOCCUS 
AUREUS TREATED WITH NEW GENTAMICIN-NIGELLA 
SATIVA FUSION EMULSION (GNFE)  
 
Yaakob KI1,5, Mohd Shafri MA*11,4, Mohd Yusof N3, Mohamed F2,4,5 
1Department of Biomedical Science, 2Department of Pharmaceutical Technology,  
3Orthopaedic Department, Kulliyyah of Medicine, International Islamic University 
Malaysia IIUM, 25200 Kuantan, Malaysia. 4International Institute of Halal 
Research & Training (INHART), Ground Floor, Block E0, Kulliyyah of 
Engineering, IIUM, P.O.Box 10, 50728, Kuala Lumpur, Malaysia. 5IKOP Sdn. 
Bhd., Pilot Plant Pharmaceutical Manufacturing, International Islamic University 
Malaysia IIUM, 25200 Kuantan, Malaysia 
 
Biofilm complicates osteomyelitis as there is antibiotic resistance and toxicity involved. In 
order to overcome the challenges of current treatment, gentamicin, the current antibiotic 
of choice for osteomyelitis, is fused with Nigella sativa oil to form an emulsion. Its efficacy 
as anti-biofilm agent is assessed using confocal laser scanning microscope (CLSM) against 
different strains of biofilm-producing Staphylococcus aureus. These strains of S.aureus 
were first allowed to express biofilm before being exposed for 24 hours to the emulsion with 
(0.1% (w/v) gentamicin; 40.2% (v/v) N.sativa. Later, the emulsion was removed and the 
biofilm was stained with fluorescence staining. The slides were viewed under CLSM at 100 
times resolution. 3D images of biofilm were reconstructed, using Image J software, to 
measure the thickness of biofilm and viability of bacteria cells. Results revealed that the 
emulsion significantly reduced biofilm thickness compared to gentamicin and N.sativa 
alone in all strains of S.aureus (Tukey’s test p < 0.05). The emulsion was also able to 
produce more than 80% and 15% surface percentage (%) of non-viable (dead) bacteria in 
the sensitive and resistant strain, respectively, at a significant level when compared to  
gentamicin and N.sativa (Tukey’s test p < 0.05). As a conclusion, this new fusion of 
gentamicin-N.sativa may be effective towards the biofilm of S.aureus, and can be developed 
further as a new promising anti-biofilm agent in osteomyelitis. 
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INTRODUCTION 
 
Osteomyelitis is an inflammation of the bone 
resulting from bacterial infection [1]. 
Without proper treatment, this disease may 
progress into the chronic stage in which the 
infection is difficult to treat. These days, 
prosthetic implantation is associated with 
most serious cases, arising from open surgery 
[2, 3]. Specific pathogens that are commonly 
found in osteomyelitis are Staphylococcus  
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aureus (60%), Enterobacteriaceae spp. 
(23%), Pseudomonas spp. (9%), and 
Streptococcus spp. (9%), with 90% of the 
infection related to prosthetic implant 
involve Staphylococcus epidermidis [4]. 
Currently, osteomyelitis, in particular, when 
involving prosthetic implant, is managed by 
impregnating gentamicin in beads form 
during a surgery [5]. However, antibiotic-
resistance, biofilm-producing bacteria which 
have become embedded within a matrix of 
extracellular polymeric substance (EPS) and 
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are able to alter gene expression, phenotype 
and protein production hence making it 
remarkably different from its planktonic 
form have also emerged [6]. This has now 
complicates the current treatment as higher 
dose of gentamicin is needed, which 
inadvertently increases the risk of gentamicin 
toxicity locally and systemically. The use of 
non-biodegradable beads also means that 
bacteria have new area to adhere to, and this 
further prolongs the infection. 
To overcome these biofilm-associated 
problems, a new fusion emulsion is formed 
aiming at reducing the amount of gentamicin, 
while at the same time increasing the anti-
biofilm and anti-bacterial effect of the new 
emulsion. Gentamicin is a type of 
aminoglycoside that is effective against a 
wide range of bacteria such as 
Staphylococcus spp., Pseudomonas spp., and 
Streptoccocus spp. Gentamicin is here 
combined with N.sativa oil which has been 
shown to possess antimicrobial properties 
against S.aureus, Pseudomonas spp., and 
Enterobacteriaceae spp. It is thought to be a 
suitable combination with gentamicin  as it is 
also able to suppress gentamicin-induced 
nephrotoxicity in rabbit [7, 8].  Hence, the 
fusion of Gentamicin-N.sativa was tested 
against different strains of S.aureus in 
anticipation of anti-biofilm properties.  
 
MATERIALS AND METHODS 
 
Test Strain 
 
The S.aureus strains were isolated from 
patients diagnosed with osteomyelitis at 
Hospital Tengku Ampuan Afzan (HTAA), 
Kuantan. Isolated S.aureus was identified by 
colony by API Identification System 
(Bioemerieux, France). A total of 3 biofilm-
producing S.aureus including 2 clinical 
isolate (sensitive and resistant to gentamicin) 
and 1 control strain (ATCC 29213) were 
used in this study. 
 
Fusion Formulation 
 
Gentamicin sulphate and N.sativa oil 
(Hemani Trading, Pakistan) were formulated 
in emulsion form, containing a combination 
of 0.1% w/v gentamicin solution  and 40.6% 
N.sativa  in a surfactants blends (Tween 20 
and Span 20), using a homogeniser for 5 
minutes. Once the milky brown emulsion 
colour was formed, it was subjected for 
stability evaluation by storing at different 
condition (8°C, 25°C, and 50°C) for certain 
period of time (7, 14 and 30 days) followed 
by centrifugation test at 5000 rpm for 5 
minutes.  
 
Biofilm Formation 
 
Thermanox coverslips (10.5 mm × 22 mm) 
(Nunc, USA) were placed horizontally at the 
bottom of 6 well plates and sterilised under 
UV light for at least 1 hour. Then, bacterial 
suspension in tryptic soy broth (TSB) with 
0.5 McFarland was added into each well and 
incubated for 24 hours at 37°C.  Medium was 
replaced with fresh TSB every 12 hours. 
After incubation, each well was decanted and 
washed 3 times with 0.85% saline for 5 
minutes.   
 
Treatments 
 
Biofilm that formed on the coverslip was 
exposed to (i) 50% emulsion, (ii) N.sativa oil 
alone, and (iii) gentamicin alone, for 24 
hours at 37°C. Untreated biofilm served as 
positive control. Biofilm that was exposed to 
95% ethanol served as negative control. 
After 24 hours, the content of each well was 
aspirated by gentle pipetting, and wells were 
washed 3 times with saline 0.85% for 5 
minutes each.  
 
Fluorescence Staining 
 
Biofilm (treated, untreated, and control) were 
stained with LIVE/DEAD Baclight L7007 
kit (Invitrogen, Canada) according to 
manufacturer’s instruction. Briefly, the stain 
was prepared by mixing 3 µL of component 
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A (1.67 mM Syto 9/ 1.67 mM Propidium 
iodide) and component B (1.67 mM Syto 9, 
18.3 mM Propidium iodide) in 994 µL of 
0.85% saline (final volume 1 mL).  Biofilm 
was then stained and incubated in the dark for 
15 minutes at room temperature (27°C). The 
stained was removed and biofilm was fixed 
with Bouin’s solution for 10 minutes. After 
fixation, each coverslip was washed with 
0.85% saline for 5 minutes. The coverslip 
were mounted on the slide with 50 µm 
spacer. 
 
CLSM Analysis 
 
Slide was viewed under confocal laser 
scanning microscope (CLSM) (Leica TCS 
SPE, German) within 48 hours after 
preparation. The excitation wavelength for 
Syto 9 was at 488 nm whereas Propidium 
Iodide was at 532 nm. The emitting light of 
fluorescent dye was detected between 480-
560 for Syto 9 and 590-750 for Propidium 
Iodide. The setting for laser power and gain 
were optimized using positive control (Syto 
9, green, viable bacteria) and negative 
control (Propidium Iodide, red, non-viable 
bacteria). Z-stack images were taken and at 
least 4 regions (n=4) on each slide were 
viewed. The series of Z-stack images were 
analysed using Image J software version 1.48 
(National Institute of Health, USA). 3D 
images of biofilm were reconstructed and the 
thickness of biofilm (bottom to top) was 
measured. Images of biofilm (top, middle 
and bottom) were selected and the surface 
percentage (%) (total area of 753 ×753 µm) 
of viable and non-viable bacteria on different 
depth of biofilm were analysed using colour 
threshold method in Image J. 
 
RESULT AND DISCUSSION 
 
Lowest biofilm thickness was seen in all 
strains of S.aureus after exposure to 
emulsion. The value was significant in 
comparison with gentamicin and N.sativa 
(Tukey’s test p < 0.05) (Figure 1). The 
effectiveness of emulsion in reducing biofilm 
may be due to synergistic effects of 
combining gentamicin with N.sativa. 
Although gentamicin and N.sativa also 
showed low biofilm thickness towards 
gentamicin sensitive S.aureus and S.aureus 
ATCC 29213, no significant different was 
seen against gentamicin resistant S.aureus 
(Figure 1).  
It was also found that treatment with the 
emulsion produced highest surface 
percentages (%) of non-viable S.aureus
 
Figure 1: The mean (n=4) thickness of S.aureus biofilm in different treatment group. (*) 
Denotes (Tukey’s test p < 0.05) compared to gentamicin; (#) denotes (Tukey’s test p < 0.05) 
compared to N.sativa; (◊) denotes (Tukey’s test p < 0.05) compared to untreated.
  
Confocal Laser Screening Microscope Analysis on Post-Biofilm Assessment of Biofilm-Producing 
Osteomyelitic Staphylococcus aureus Treated with New Gentamicin-Nigella sativa Fusion Emulsion 
(GNFE) 
                                        Malaysian Journal of Microscopy Vol. 11 (2015)                 71 
regardless of biofilm depth (Figure 2; A, B, 
and C) with significant difference  to the  
gentamicin- and N.sativa oil-only groups 
(Tukey’s test p < 0.05). More than 80% of 
non-viable bacteria were seen in S.aureus 
gentamicin sensitive and more than 98% in 
S.aureus ATCC 29213 (Figure 2; A and C). 
 
 
(a) 
 
 
(b) 
 
 
(c)  
 
Figure 2: The surface percentage (%) of 
non-viable (A) S.aureus, gentamicin 
sensitive (clinical isolate), (B) S.aureus, 
gentamicin resistant (clinical isolate) and 
(C) S.aureus ATCC 29213. (*) Denotes 
(Tukey’s test p < 0.05) compared to 
gentamicin; (#) denotes (Tukey’s test p < 
0.05) compared to N.sativa. 
 
 Furthermore, in gentamicin 
resistant S.aureus, treatment with emulsion 
produced 15% to 30% (top, middle, and 
bottom) of non-viable bacteria. Both 
Gentamicin and N.sativa produced lower 
percentage of non-viable bacteria than 
emulsion in all S.aureus strains. 
 The ability of an antimicrobial 
agent to penetrate biofilm without losing its 
efficacy is really important in combating 
biofilm. Inability to kill bacteria at the 
bottom of biofilm will cause viable bacteria 
that remain undisturbed at the bottom of 
biofilm to growth [7]. In this study, it was 
shown that the formulated emulsion could 
produce anti-biofilm activities by reducing 
biofilm thickness and percentage of viable 
surface S.aureus. In comparison to the 
gentamicin- and N.Sativa-only groups, the 
emulsion appears to be able to effectively kill 
bacteria within biofilm. Nevertheless, the 
percentage of death bacteria at the bottom 
was less than at the top surface of biofilm 
(Figure 2).  The overlapping fluorescence 
staining of syto 9 (green) and propidium 
iodide (red) within bacteria cells indicates 
that the damage of bacteria cell wall is 
variable according to biofilm depths (Figure 
3; A and B). Three colours (yellow, orange, 
and red) showed different degree of severity 
of the cell wall damage. In the Z – stack 
images (Figure 3; A), the colour changed 
from the bottom to the top, from yellow 
(slight damage) to orange (severe damage) 
and to red (complete damage). 
 As far as it concern, this is the first 
study on the combination of antibiotic and 
natural product, especially on the fusion of 
gentamicin and N.sativa. Most of the 
previous studies were only focusing against 
planktonic bacteria such as by Braga et al, 
(2005) that reported combination of 
pomegranate with gentamicin, 
chloramphenicol, ciprofloxacin, ampicillin, 
tetracycline and oxacillin were effective 
towards methicillin resistant S.aureus 
(MRSA) [8]. Another study by Mossa et al, 
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(2004) showed that combination of totarol, 
ferulenol and plumbagin increase isoniazid 
potency against Mycobacterium sp. [9]. 
Such studies have showed that the fusion of 
antibiotic and natural product might be the 
future in the development of new 
antimicrobial agents. 
 
 
(a) 
 
 
(b) 
Figure 3: CLSM images of S.aureus 
gentamicin sensitive treated with 
gentamicin-N.sativa fusion emulsion (A) 
Montage of Z-stack images and (B) 3D-
reconstructed image of biofilm. 
 
CLSM is a powerful tool in biofilm 
analysis [10]. It has the ability to reconstruct 
3D structure of biofilm and quantified the 
numbers of bacteria within the matrix using 
proper fluorescence staining method. 
Furthermore, CLSM can be used on hydrated 
biological structure without fixation. Hence, 
it is a non-destructive technique and suitable 
for live cell viewing [11]. Many studies on 
biofilm have been using CLSM and it has 
become a standard tool for biofilm 
investigation [12]. 
 
CONCLUSION 
 
Newly formulated gentamicin-N.sativa 
fusion emulsion (GNFE) is effective towards 
biofilm of S.aureus, thus can be developed 
further as a new promising anti-biofilm agent 
for osteomyelitis. 
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